CD8A and neoplasm: Preclinical data from murine models have demonstrated that lenvatinib induces tumour immune microenvironment modifications (e.g., reduction of tumour-associated macrophages (TAMs) and increase of activated CD8+ T cells secreting interferon (IFN)-γ+ and granzyme B).